Tax
Foreign Tax (Deferred)
Vertex Pharmaceuticals Foreign Tax (Deferred) remained flat by 0.0% to $9.58M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 72.4%, from $34.65M to $9.58M. Over 2 years (FY 2023 to FY 2025), Foreign Tax (Deferred) shows a downward trend with a -16.8% CAGR.
Analysis
StatementIncome Statement
SectionTax
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ4 2025
How to read this metric
An increase suggests higher future tax liabilities in foreign jurisdictions due to timing differences, while a decrease may indicate the reversal of such liabilities.
Detailed definition
This metric represents the portion of the total deferred income tax provision attributable to foreign jurisdictions. It...
Peer comparison
Common in multinational corporations with significant international tax footprints.
Metric ID:
msft_deferred_foreign_tax_expenseHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $55.30M | $138.60M | $38.30M |
| YoY Change | — | +150.6% | -72.4% |
Range$38.30M – $138.60M
CAGR-16.8%
Avg YoY Growth+39.1%
Median YoY Growth+39.1%
Foreign Tax (Deferred) at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's foreign tax (deferred)?
- Vertex Pharmaceuticals (VRTX) reported foreign tax (deferred) of $9.58M in Q4 2025.
- How has Vertex Pharmaceuticals's foreign tax (deferred) changed year-over-year?
- Vertex Pharmaceuticals's foreign tax (deferred) decreased by 72.4% year-over-year, from $34.65M to $9.58M.
- What is the long-term trend for Vertex Pharmaceuticals's foreign tax (deferred)?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's foreign tax (deferred) has grown at a -16.8% compound annual growth rate (CAGR), from $55.30M to $38.30M.
- What does foreign tax (deferred) mean?
- The amount of deferred income tax expense specifically related to foreign operations.